Beyond sepsis pathophysiology with cytokines: What is their value as biomarkers for disease severity?

Memorias do Instituto Oswaldo Cruz

Volumn 100, Issue SUPPL. 1, 2005, Pages 217-221

  Bozza, Fernando A ^a   Bozza, Patrícia T ^b   Castro Faria Neto, Hugo C ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Biomarkers; Cytokines; Sepsis; Stratification

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROCALCITONIN;

CONFERENCE PAPER; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE MARKER; DISEASE SEVERITY; FLOW CYTOMETRY; HUMAN; LETHALITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; RELIABILITY; SEPSIS; SEPTIC SHOCK; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 18844391752     PISSN: 00740276     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0074-02762005000900037     Document Type: Conference Paper

References (41)

1. Abbate A, Biondi-Zoccai GG, Brugaletta S, Liuzzo G, Biasucci LM 2003. C-reactive protein and other inflammatory biomarkers as predictors of outcome following acute coronary syndromes. Semin Vasc Med 3: 375-384.
2. Angus DC, Wax RS 2001. Epidemiology of sepsis: an update. Crit Care Med 29: S109-116.
3. Bacher M, Meinhardt A, Lan HY, Mu W, Metz CN, Chesney JA et al. 1997. Migration inhibitory factor expression in experimentally induced endotoxemia. Am J Pathol 150: 235-246.
4. Bacher M, Metz CN, Calandra T, Mayer K, Chesney J, Lohoff M et al. 1996. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93: 7849-7854.
5. Beishuizen A, Thijs LG, Haanen C, Vermes I 2001. Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86: 2811-2816.
6. Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W et al. 1993. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365: 756-759.
7. Bozza FA, Gomes RN, Japiassu AM, Scares M, Castro-Faria-Neto HC, Bozza PT et al. 2004. Macrophage migration inhibitory factor levels correlate with fatal outcome in sepsis. Shock 22: 309-313.
8. Bozza M, Satoskar AR, Lin G, Lu B, Humbles AA, Gerard C et al. 1999. Targeted disruption of migration inhibitory factor gene reveals its critical role in sepsis. J Exp Med 189: 341-346.
9. Calandra T, Bucala R 1995. Macrophage migration inhibitory factor: a counter-regulator of glucocorticoid action and critical mediator of septic shock. J Inflamm 47: 39-51.
10. Calandra T, Bernhagen J, Mitchell RA, Bucala R 1994. The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor. J Exp Med 179: 1895-1902.
11. Calandra T, Echtenacher B, Roy DL, Pugin J, Metz CN, Hultner L et al. 2000. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6: 164-170.
12. Calandra T, Spiegel LA, Metz CN, Bucala R 1998. Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of gram-positive bacteria. Proc Natl Acad Sci USA 95: 11383-11388.
13. Chalfin DB, Holbein ME, Fein AM, Carlon GC 1993. Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. Jama 269: 249-254.
14. Clec'h C, Ferriere F, Karoubi P, Fosse JP, Cupa M, Hoang P et al. 2004. Diagnostic and prognostic value of procalcitonin in patients with septic shock. Crit Care Med 32: 1166-1169.
15. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J et al. 2004. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32: 858-873.
16. Donnelly SC, Haslett C, Reid PT, Grant IS, Wallace WA, Metz CN et al. 1997. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3: 320-323.
17. Gando S, Nishihira J, Kobayashi S, Morimoto Y, Nanzaki S, Kemmotsu O 2001. Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med 27: 1187-1193.
18. Gattas DJ, Cook DJ 2003. Procalcitonin as a diagnostic test for sepsis: health technology assessment in the ICU. J Crit Care 18: 52-58.
19. Glauser MP 2000. Pathophysiologic basis of sepsis: considerations for future strategies of intervention. Crit Care Med 28: S4-8.
20. Gogos CA, Drosou E, Bassaris HP, Skoutelis A 2000. Proversus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis 181: 176-180.
21. Hengst JM 2003. The role of C-reactive protein in the evaluation and management of infants with suspected sepsis. Adv Neonatal Care 3: 3-13.
22. Heyland DK, Hopman W, Coo H, Tranmer J, McColl MA 2000. Long-term health-related quality of life in survivors of sepsis. Short Form 36: a valid and reliable measure of health-related quality of life. Crit Care Med 28: 3599-3605.
23. Kox WJ, Volk T, Kox SN, Volk HD 2000. Immunomodulatory therapies in sepsis. Intensive Care Med 26 (Suppl 1): S124-128.
24. Lai KN, Leung JC, Metz CN, Lai FM, Bucala R, Lan HY 2003. Role for macrophage migration inhibitory factor in acute respiratory distress syndrome. J Pathol 199: 496-508.
25. Lehmann LE, Novender U, Schroeder S, Pietsch T, von Spiegel T, Putensen C et al. 2001. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27: 1412-1415.
26. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D et al. 2003. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29: 530-538.
27. Marshall JC, Vincent JL, Fink MP, Cook DJ, Rubenfeld G, Foster D et al. 2003. Measures, markers, and mediators: toward a staging system for clinical sepsis. A report of the Fifth Toronto Sepsis Roundtable, Toronto, Ontario, Canada, October 25-26, 2000. Crit Care Med 31: 1560-1567.
28. Mendonca-Filho HTF, Gomes RV, Campos LAA, Tura B, Nunes EM, Gomes RN, Bozza F, Bozza PT, Castro Faria Neto HC 2004. Circulating levels of macrophage migration inhibitory factor are associated with mild pulmonary dysfunction after cardio pulmonary bypass. Shock 22: 533-537.
29. Perl TM, Dvorak L, Hwang T, Wenzel RP 1995. Long-term survival and function after suspected gram-negative sepsis. Jama 274: 338-345.
30. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E 1993. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565-575.
31. Polderman KH, Girbes AR 2004. Drug intervention trials in sepsis: divergent results. Lancet 363: 1721-1723.
32. PX D 1946. Enquete permanent dans les centres anticancereaux. Bull Inst Natl Hyg 1: 70-75.
33. Rau B, Kruger CM, Schilling MK 2004. Procalcitonin: improved biochemical severity stratification and postoperative monitoring in severe abdominal inflammation and sepsis. Langenbecks Arch Surg 389: 134-144.
34. Riedemann NC, Ward PA 2003. Anti-inflammatory strategies for the treatment of sepsis. Expert Opin Biol Ther 3: 339-350.
35. Riedemann NC, Guo RF, Ward PA 2003. The enigma of sepsis. J Clin Invest 112: 460-467.
36. Roger T, David J, Glauser MP, Calandra T 2001. MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924.
37. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J 2004. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39: 206-217.
38. Tanaka H, Ishikawa K, Nishino M, Shimazu T, Yoshioka T 1996. Changes in granulocyte colony-stimulating factor concentration in patients with trauma and sepsis. J Trauma 40: 718-725.
39. Van Amersfoort ES, Van Berkel TJ, Kuiper J 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin Microbiol Rev 16: 379-414.
40. Wheeler AP, Bernard GR 1999. Treating patients with severe sepsis. N Engl J Med 340: 207-214.
41. Willerson JT, Ridker PM 2004. Inflammation as a cardiovascular risk factor. Circulation 109: II2-10.